trending Market Intelligence /marketintelligence/en/news-insights/trending/aVSkFcxV1zKrwpqh4KTBiw2 content esgSubNav
In This List

Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Eli Lilly and Co. said the phase 3 trial of Verzenio as a monotherapy in KRAS-mutated, advanced non-small lung cancer failed to meet its main goal.

Results from the JUNIPER study showed that Verzenio was not superior to Roche Holding AG and Astellas Pharma Inc.'s Tarceva, or erlotinib, and did not meet the end goal for overall survival.

However, an analysis of the secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in the Verzenio arm of the study.

The U.S. Food and Drug Administration approved Verzenio, or abemaciclib, in September to treat advanced or metastatic breast cancer that has progressed following endocrine therapy.